Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R)...

Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of
Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB

ALLEGAN, Mich., June 24 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq:
PRGO; TASE) today announced that its partner Synthon Pharmaceuticals, Inc. has
filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution
2.5mg/5ml, a generic version of Xyzal(R) solution 2.5mg/5ml. Under terms of an
exclusive agreement between the companies, Perrigo has sales and marketing
rights in Synthon's Levocetirizine products. The Company believes that
Synthon is the first to file an ANDA with a Paragraph IV certification against
Xyzal(R) solution that can entitle it to 180 days of generic exclusivity upon
approval.

Xyzal(R) solution (Levocetirizine solution) 2.5mg/5ml is indicated for relief
of symptoms associated with allergies and treatment of hives, and has sales of
approximately $10 million annually, as measured by Wolters Kluwer Health for
the quarter ending April 2009.

Synthon filed its ANDA for Levocetirizine solution 2.5 mg/5ml containing a
Paragraph IV Certification with the U.S. Food & Drug Administration and
notified UCB Inc., the New Drug Application holder for Xyzal(R) solution and
Sepracor Inc., the listed patent owner, of its filing. On June 17, 2009,
Sepracor and UCB filed suit alleging patent infringement in the United States
District Court for the Eastern District of North Carolina against Synthon.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another
example of our investment in new products and expansion of our product
portfolio. The first to file status also reflects Perrigo's continued focus on
being first to market with new products. As always, Perrigo is committed to
making quality healthcare more affordable for our customers."

Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and generic prescription pharmaceuticals,
nutritional products, active pharmaceutical ingredients (API) and consumer
products. The Company is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. The Company's primary
markets and locations of manufacturing and logistics operations are the United
States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet
(http://www.perrigo.com).

Synthon Pharmaceuticals, Inc., with its U.S. headquarters and laboratories
located in Research Triangle Park, North Carolina, markets generic drugs under
its own name and through partnerships with other leading pharmaceutical
companies. Synthon currently holds several approved, or tentatively approved,
drug applications and our pipeline contains more than a dozen products that
are expected to be filed with the FDA within the next few years. Synthon
Pharmaceuticals, Inc. is part of the Synthon group, a global privately held
specialty pharma company with offices, laboratories and manufacturing sites in
the Netherlands, Spain, Czech Republic, Australia, Argentina, Chile and the
USA. Visit Synthon on the Internet (http://www.synthon.com).

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 28, 2008, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Arthur J. Shannon, Vice President, Investor Relations and Communication,
+1-269-686-1709, ajshannon@perrigo.com; Daniel B. Willard, Manager, Investor
Relations and Communication, +1-269-686-1597, dbwillard@perrigo.com, both of
Perrigo Company